Mural Oncology Cuts 90% of Workforce Following Failed Cancer Immunotherapy Trials
Mural Oncology is discontinuing all clinical development of nemvaleukin alfa after the immunotherapy failed to meet target goals in melanoma and ovarian cancer trials.
Hypersomnia Pipeline Shows Promise with 10+ Emerging Therapies in Development
DelveInsight's latest report reveals 8+ companies developing 10+ therapies for hypersomnia, with Avadel's Lumryz, Zevra's KP1077, and Alkermes' ALKS 2680 among the key candidates advancing through clinical trials.
Olanzapine and Samidorphan Combination Shows Sustained Schizophrenia Symptom Control in Long-Term Study
Long-term data reveals that the combination of olanzapine and samidorphan (OLZ/SAM) maintains symptom control in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder over four years.
Alkermes Presents Positive Phase 1b Data for ALKS 2680 in Narcolepsy Type 2 and Idiopathic Hypersomnia
Alkermes' ALKS 2680 demonstrates improved wakefulness compared to placebo in patients with narcolepsy type 2 (NT2) in a Phase 1b study.
Centessa's ORX750 Advances to Phase 2 for Narcolepsy and Idiopathic Hypersomnia After Promising Phase 1 Results
Centessa Pharmaceuticals' ORX750, an orexin receptor 2 (OX2R) agonist, demonstrated significant improvements in wakefulness in sleep-deprived healthy volunteers.